Haemonetics (NYSE: HAE) Price Target Raised Amid Strong Performance
BTIG analyst Marie Thibault has raised the price target for Haemonetics to $142.00, indicating a potential 16.5% upside from the current share price. The company reported strong financial results, with adjusted earnings reaching $1.35 per share and revenue climbing to $357.76 million, both…